Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31584153 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL22216857 | 0.87 | KDM4E (0.54) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL30465534 | 0.87 | KDM4E (0.54) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL28266315 | 0.83 | ALDH1A1 (0.40) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL26599922 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL9000436 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL29792739 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL19839823 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL19839824 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1GLAGAALMNA | |
| SCHEMBL21056702 | 0.79 | KDM4C (0.53) | KDM4EALDH1A1GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-03-17 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-109071497-B | PAD4 heteroaryl inhibitors | 帕德罗科治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3419969-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| CN-105980378-A | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2016-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885ALDH1A1 956/4885GLA 3805/4885 |
| US-11897866-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885ALDH1A1 956/4885GLA 3805/4885 |
| US-20220081418-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885ALDH1A1 956/4885GLA 3805/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | KDM4E 117/4885ALDH1A1 956/4885GLA 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.